Entero Therapeutics Faces Delisting Concerns
Ticker: GRDX · Form: 8-K · Filed: Apr 14, 2025 · CIK: 1604191
| Field | Detail |
|---|---|
| Company | Entero Therapeutics, Inc. (GRDX) |
| Form Type | 8-K |
| Filed Date | Apr 14, 2025 |
| Risk Level | high |
| Sentiment | bearish |
Sentiment: bearish
Topics: delisting, compliance, corporate-actions
TL;DR
Entero Therapeutics might get delisted, former First Wave BioPharma.
AI Summary
Entero Therapeutics, Inc. filed an 8-K on April 14, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule or standard. The company was formerly known as First Wave BioPharma, Inc. and has undergone several name changes.
Why It Matters
This filing indicates potential financial distress or non-compliance with stock exchange rules, which could lead to the company's shares being removed from trading.
Risk Assessment
Risk Level: high — A notice of delisting directly threatens the company's ability to remain publicly traded, posing a significant risk to investors.
Key Players & Entities
- Entero Therapeutics, Inc. (company) — Registrant
- First Wave BioPharma, Inc. (company) — Former company name
- April 11, 2025 (date) — Earliest event reported
- April 14, 2025 (date) — Filing date
FAQ
What specific listing rule or standard has Entero Therapeutics failed to satisfy?
The filing does not specify the exact rule or standard that Entero Therapeutics has failed to satisfy, only that a notice has been issued.
What is the earliest event date reported in this 8-K filing?
The earliest event reported is April 11, 2025.
When was this 8-K filing submitted to the SEC?
This 8-K filing was submitted on April 14, 2025.
What were some of Entero Therapeutics' previous company names?
Entero Therapeutics, Inc. was formerly known as First Wave BioPharma, Inc., AzurRx BioPharma, Inc., and BioPharma d'Azur, Inc.
Where is Entero Therapeutics, Inc. incorporated?
Entero Therapeutics, Inc. is incorporated in Delaware.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on April 14, 2025 regarding Entero Therapeutics, Inc. (GRDX).